The Emirates Drug Establishment

What The Emirates Drug Establishment does

The Emirates Drug Establishment (EDE) is the sole federal regulatory authority in the United Arab Emirates responsible for overseeing all medical and pharmaceutical products, established by Federal Decree-Law No. (28) of 2023 on 29 September 2023. Its mandate spans drug registration and approval, medical device marketing authorization, clinical trial evaluation, pharmacovigilance, Good Manufacturing Practice certification, and regulation of veterinary medications, agricultural products, blood derivatives, genetically modified organisms, stem cells, and medicated cosmetics. EDE is headquartered at Eco Plaza in Masdar City, Abu Dhabi, with an additional office in Dubai, and operates under the leadership of Chairman H.E. Saeed bin Mubarak Al Hajeri, Vice Chairman Dr. Maha Taysir Barakat, and Director General Dr. Fatima Al Kaabi.

EDE generates revenue primarily through publicly disclosed fee-based regulatory services, including clinical trial evaluation (5,000 AED), medical warehouse licensing (application 100 AED, inspection 1,000 AED per instance, final licensing 7,500-10,000 AED), and additional charges for product registration, licensing, and pharmacovigilance activities. The establishment also receives implicit government funding as a federal entity. Its go-to-market is institutional rather than commercial: EDE engages pharmaceutical companies, medical device manufacturers, government entities, and the public through its website (www.ede.gov.ae), social media channels, press releases, and a toll-free call center.

On the technology side, EDE is transitioning to Agentic AI for pharmaceutical regulation across medicine registration, inspections, and supply chain oversight, supported by a centralized Registered Medical Product Directory and AI data analytics infrastructure. Strategic partnerships with Novo Nordisk, AstraZeneca, Douglas Pharmaceuticals, and AFT Pharmaceuticals — alongside first-in-world approvals of treatments such as Etcamah and Jascayd — signal EDE's positioning as an agile, internationally engaged regulator targeting the UAE's emergence as a regional pharmaceutical hub.

Name

The Emirates Drug Establishment

Legal name

Emirates Drug Establishment

Website

https://ede.gov.ae

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

101–250 employees

Short description

The Emirates Drug Establishment (EDE) is the sole UAE federal regulatory authority for all medical and pharmaceutical products, including drugs, medical devices, veterinary medications, and agricultural products, serving pharmaceutical companies, manufacturers, and the public through licensing, registration, and pharmacovigilance services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Services

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industries

Medical Device Regulators (HLAJADAC), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF), Regulatory Affairs, Labeling & Advertising/Promotion Compliance (HLAJADAI), Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

Keywords

• Pharmaceutical regulation
• Drug registration
• Medical device approval
• Clinical trial evaluation
• Pharmacovigilance services

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Regulatory Service Fees: The establishment charges fees for various regulatory services including clinical trial evaluations, licensing, market authorization, and product registration. Fees are publicly disclosed for services such as medical product evaluation for pharmacological research and clinical trials (5,000 AED), medical warehouse licensing (application fees of 100 AED, inspection fees of 1,000 AED per instance, and final licensing fees of 7,500-10,000 AED depending on facility type).

Pricing tiers

Distribution channels2 records

Marketing channels4 records

Core offering

The Emirates Drug Establishment is the sole federal regulatory authority in the UAE responsible for regulating all medical and pharmaceutical products, including medical devices, blood derivative products, genetically modified organisms, stem cells, medicated cosmetics, veterinary medications, and agricultural products. It delivers regulatory services such as drug registration and market authorization, medical device marketing approval, clinical trial evaluation, pharmacovigilance monitoring, GMP certification, and licensing of pharmaceutical warehouses and facilities, supported by a public Registered Medical Product Directory and an Agentic AI-enabled regulatory operations framework.

Product overview

The Emirates Drug Establishment (EDE) is the sole federal regulatory authority in the UAE responsible for regulating all medical and pharmaceutical products. Rather than offering a unified software product, EDE provides a comprehensive portfolio of regulatory services including drug registration and approval, medical device marketing approval, clinical trial evaluation, pharmacovigilance, and Good Manufacturing Practice certification. EDE also regulates veterinary products, agricultural products (pesticides and fertilizers), and maintains the Registered Medical Product Directory. The organization is transitioning to Agentic AI to build a more proactive regulatory ecosystem for medicine registration, inspections, and pharmaceutical supply chain oversight.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Registration and Approval Services Regulatory services for evaluating and approving pharmaceutical products, biological products, and healthcare products for market authorization in the UAE. Target users are pharmaceutical companies seeking market entry.
• Medical Device Marketing Approval Services for obtaining marketing approval for medical devices, including the ability to designate additional agents for importing and distributing medical products. Target users are medical device manufacturers.
• Clinical Trial Evaluation Service for receiving, evaluating, and approving medical products for pharmaceutical research and clinical trials in the UAE, with a 90 working-day processing time and a 5,000 AED fee. Target users are clinical trial sponsors and CROs.
• Pharmacovigilance Services Monitoring and ensuring safety of pharmaceutical products post-market, including adverse event reporting and product recall management. Target users are pharmaceutical companies and the general public.
• Good Manufacturing Practice Certification Certification services for pharmaceutical facilities and medical warehouses to ensure compliance with manufacturing and storage standards. Target users are pharmaceutical manufacturers and warehouse operators.
• Veterinary Products Regulation Regulation and licensing services for veterinary medications, veterinary pharmaceutical facilities, and related products. Target users are veterinary pharmaceutical companies and facilities.
• Agricultural Products Regulation Services for regulating pesticides, fertilizers, and agricultural supplements including registration, import permits, and compliance certification. Target users are agricultural input suppliers and importers.
• Registered Medical Product Directory Online registry of all registered medical and pharmaceutical products in the UAE, accessible to the public and industry.
• Medical Warehouse Licensing Licensing service for medical warehouses, including application review, on-site inspection, and final license issuance. Target users are pharmaceutical storage and distribution operators.

Quantifiable outcome

• UAE became the first country in the world to approve Etcamah, an innovative ESR1-targeted breast cancer treatment from AstraZeneca
• +3 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Five partnerships are on record, tiered core and flagship.

• Douglas Pharmaceuticals (New Zealand)coreStrategic or Co-development Partner · 13 June 2026Meeting held between EDE Chairman and Douglas Pharmaceuticals representatives to explore deeper partnerships and expanded collaboration. Douglas Pharmaceuticals has specialized R&D and manufacturing facilities exporting products to more than 55 markets worldwide, with advanced expertise in soft gelatin capsule manufacturing. Discussions included a research project developing treatment for treatment-resistant depression using enhanced extended-release formulation that has completed Phase II clinical trials.
• AFT Pharmaceuticals (New Zealand)coreStrategic or Co-development Partner · 13 June 2026Meeting held between EDE Chairman and AFT Pharmaceuticals CEO Dr Hartley Atkinson to explore investment and collaboration opportunities. AFT markets products in 87 countries worldwide and considers UAE one of its key markets in the region. The company commended the UAE's regulatory environment for offering clarity, transparency, and streamlined procedures. Discussions included R&D projects on innovative therapies for unmet medical needs, rare disease programs, and development of safer intravenous iron treatments and medicines that can be stored without refrigeration.
• Novo NordiskflagshipStrategic or Co-development Partner · 8 June 2026EDE signed an MoU with Novo Nordisk to strengthen cooperation in pharmaceutical manufacturing through advanced technologies and support the development of an innovative, sustainable pharmaceutical ecosystem in the UAE. The partnership includes collaboration in supply chain security by increasing in-country value, talent development and capacity-building programs, and creating a supportive regulatory environment that accelerates introduction of innovative therapies. Novo Nordisk also established a regional distribution center in the UAE, one of only three globally, serving up to 70 countries and reaching over 2.6 million patients.
• International Regulatory BodiescoreStrategic or Co-development PartnerEDE collaborates with international regulatory bodies to exchange knowledge and harmonize regulations while maintaining the UAE's commitment to excellence and ethical practices. The establishment partners with international organizations to attract global expertise, promote knowledge sharing, and ensure patient safety through rigorous oversight.
• AstraZenecaflagshipStrategic or Co-development PartnerEDE approved AstraZeneca's Etcamah, an innovative ESR1-targeted breast cancer treatment, making the UAE the first country in the world to make this treatment available. The approval was based on findings from the Phase III SERENA-6 trial. EDE emphasized collaboration with partners across the UAE to improve treatment outcomes for eligible patients.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Health Canada: Canada's federal health product regulator with broad scope over drugs, devices, and biologics. Comparable to EDE in covering human pharmaceuticals plus adjacent product categories under a single federal authority.
• European Medicines Agency (EMA): Centralized EU regulator for human and veterinary medicines, with deep procedural maturity and harmonized recognition across 27+ countries. EDE's international collaboration efforts and harmonization ambitions directly compare against EMA's network model.
• U.S. Food and Drug Administration (FDA): The benchmark national regulator of drugs, biologics, and medical devices in the world's largest pharma market. EDE is positioning itself against FDA's gold-standard review timelines and is explicitly racing to beat FDA on first-in-world approvals such as Jascayd.
• Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Japan's regulator for pharmaceuticals and medical devices, with a strong track record on accelerated review of innovative therapies. A relevant peer for EDE's ambitions to be among the earliest global approvers of breakthrough treatments.
• National Medical Products Administration (NMPA) China: China's national regulator for drugs and medical devices, which approved Jascayd before the UAE. NMPA is both a benchmark and a competitor to EDE for first-in-region approvals of innovative therapies.

Direct peers

• Swissmedic: Switzerland's national medicines and medical devices authority, recognized for scientific rigor and premium-market relevance. Comparable in scale and mandate to EDE, and a relevant model for a small, high-credibility regulator.
• Saudi Food and Drug Authority (SFDA): Saudi Arabia's federal regulator covering drugs, biologics, medical devices, and food — the most direct regional comparator to EDE within the Gulf. Both authorities compete to be the Gulf's preferred entry point for multinational pharma launches.
• Health Sciences Authority (HSA) Singapore: Singapore's integrated regulator for health products including pharmaceuticals, medical devices, and complementary medicines. HSA is a comparable small-but-mature Asian regulator often cited as a benchmark for efficient approval pathways.
• Therapeutic Goods Administration (TGA) Australia: Australia's regulator for medicines, medical devices, and biologics, known for fast-track and provisional approval pathways. Directly comparable in mandate and in competing for early-launch positioning against larger markets.
• UK Medicines and Healthcare products Regulatory Agency (MHRA): UK's standalone medicines and devices regulator, recognized for post-Brexit agility and accelerated pathways. MHRA is a closer model than FDA/EMA for what EDE aspires to be: a smaller, agile, AI-enabled national authority.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/EDE_UAE
• YouTubeyoutube.com/@Emiratesdrugestablishment
• Facebookfacebook.com/emiratesdrugestablishment
• LinkedInlinkedin.com/company/emirates-drug-establishment
• Instagraminstagram.com/ede_uae
• TikToktiktok.com/@ede_uae

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Emirates Drug Establishment